A phase II study of interferon‐α, interleukin‐2 and 5‐fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation

This study confirms the activity of this regimen in patients of good performance status, with limited sites of disease and in those who are fit for nephrectomy, but also showed that treatment was associated with considerable toxicity. The administration of IL-2 is associated with protease activation which may be a suitable target for pharmacological intervention in attempts to ameliorate toxicity.